PositiveID Corporation Signs Space Act Agreement With NASA; Momenta to Present Data Supporting Sialylation Print E-mail
By Staff and Wire Reports   
Monday, 05 May 2014 18:23
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 5, 2014.
PositiveID Corporation (OTCMKTS:PSID), a developer of biological detection and diagnostics solutions, announced today that it has signed a Space Act Agreement with NASA's Ames Research Center to collaborate on testing the Company's Firefly Dx detection system ("Firefly") as a platform for biological research and commercial development for ground and space applications.

PositiveID's Firefly Dx is a point-of-need, handheld system designed to deliver molecular diagnostic results using real-time TaqMan(R) PCR (polymerase chain reaction) chemistry. Firefly is intended to derive results from a sample in less than 20 minutes at the point of need, compared to two to four hours for a lab device. Quicker, accurate diagnostics derived from Firefly may lead to more rapid and effective treatment than what is currently available with existing systems. Firefly is being developed to meet the growing need for more rapid and accurate point-of-need diagnostics that will enable hospitals, first responders, and other providers to save lives.

Under this Space Act Agreement, NASA will assess the Company's Firefly Dx technology for potential ground and space applications, while PositiveID will assess the technology to improve its development of the Firefly Dx hardware for extreme environments, such as Department of Defense field applications.

William J. Caragol, Chairman and CEO of PositiveID, said, "We are very proud to collaborate with NASA's world-class team of scientists and researchers on the continued development of Firefly to advance mission-critical applications for point-of-need diagnostics, both in space and on the front lines to protect our nation from future bioterrorism threats."


Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA)
, a biotechnology company specializing in the characterization and engineering of complex drugs, will present its approach to designing novel therapeutics by applying site-specific sialylation to Fc glycans in IVIg, monoclonal antibodies, and other recombinant Fc-containing proteins, in a presentation entitled "Embracing Complexity: Understanding IVIg to Rationally Engineer Novel Therapeutics". The presentation will be given by Tony Manning, Ph.D., Vice President of Research at Momenta, at 12:10 pm on Monday, May 5, 2014 at the PEGS annual meeting in Boston.

Momenta has thoroughly characterized a wide range of IVIg preparations to understand the detailed composition of this plasma-derived product. Using molecular, cellular, and animal models of disease, supplemented by an analysis of samples from human patients treated with IVIg, the company has developed a detailed understanding of the biological basis for the therapeutic effects of IVIg. Momenta scientists now have a broad and comprehensive understanding of the composition of IVIg and its mechanism of action as an anti-inflammatory therapeutic. This research has informed the company's approach to the rational design of several novel, differentiated therapeutic agents.

Momenta has also optimized the process for applying site-specific sialylation to Fc glycans in antibodies, including IVIg and monoclonal antibodies, as well as other recombinant Fc-containing proteins. In his presentation, Dr. Manning will present data that demonstrate the enhanced anti-inflammatory activity of these sialylated agents across a broad range of animal models of autoimmune disease, including inflammatory arthritis, immune thrombocytopenic purpura (ITP), pemphigus, and experimental autoimmune encephalomyelitis (EAE). Finally, Dr. Manning will discuss how this research has led to approaches for rationally engineering other novel recombinant product candidates which display potential as broad anti-inflammatory therapeutics.

Also Monday:

ActiveCare Inc. (OTCQB:ACAR)
, a leader in diabetes management and wellness services for self-insured employers nationwide, today announced that Mr. Michael Jones, President, will be presenting at the Sidoti Semi-Annual Microcap Conference on Friday, May 9, 2014.

Advaxis, Inc. (Nasdaq:ADXS)
, a biotechnology company developing cancer immunotherapies, announced it intends to initiate a clinical development program with its product candidate, ADXS-cHER2, for the treatment of pediatric osteosarcoma. ADXS-cHER2 is an immunotherapy that targets the HER2 oncogene, which is overexpressed in certain solid-tumor cancers, including pediatric bone cancer and breast cancer.

Alcobra Ltd. (Nasdaq:ADHD)
, an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced the presentation of data from a successful Phase IIb study of its proprietary drug candidate MDX (Metadoxine Extended Release) in adults with Predominantly Inattentive ADHD (PI-ADHD) at the 167th Annual Meeting of the American Psychiatric Association (APA).

Amarin Corporation plc (Nasdaq:AMRN)
, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2014 financial results and provide an operational update on Friday, May 9, at 8:00 a.m. ET.

Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS),
a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced that it has acquired additional rights for its flagship Alzheimer's blood diagnostic LymPro Test ® from Memory Dx, LLC.

Applied Genetic Technologies Corporation (Nasdaq:AGTC)
, a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, announced that Guo-jie Ye, Ph. D., Director, Research and Pre-Clinical Studies, presented preclinical data related to the company's achromatopsia gene therapy program yesterday in an oral session at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. ARVO is taking place from May 4 – 8, 2014, at the Orlando Convention Center in Orlando, Fl.

Arno Therapeutics, Inc. (OTCQB:ARNI)
, a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that abstracts outlining two, separate ongoing Phase I clinical trials evaluating its investigational lead compound onapristone have been accepted for poster presentation at the upcoming 50th American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30 – June 3, 2014 in Chicago, Illinois.

Balchem Corporation (Nasdaq:BCPC)
reported as follows (unaudited) for the period ended March 31, 2014.

Cancer Genetics, Inc. (Nasdaq:CGIX)
, an emerging leader in DNA-based diagnostics, today announced it has received CLIA and New York state approvals for clinical use of its proprietary mature B-cell neoplasm array, or MatBA® for Follicular Lymphoma (MatBA®-FL) and Mantle-Cell Lymphoma (MatBA®-MCL).

Cellectar Biosciences, Inc. (OTCQX:CLRB)
, a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that it has received notification from the U.S. Food and Drug Administration (FDA) granting Cellectar's request for orphan drug designation for I-124-CLR1404 as a diagnostic for the management of glioma, the most common and aggressive form of brain cancer.

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP),
today announced that the Japanese Patent and Trademark Office issued two patents broadening the exclusivity of sapacitabine, the Company's lead clinical candidate.

Eternity Healthcare Inc. (OTCBB:ETAH),
a medical device and diagnostic company announced today that it has completed patient selection for the clinical trial comparing the Comfort-in™ Needle-free Injection System versus the standard needle process, for patients undergoing fertility treatments using the drug Gonadotropins.

FutureWorld (OTCQB: FWDG)
, a U.S. Diversified Holding Company formed to capitalize on the burgeoning technology markets globally, announces today that it has closed the acquisition of MedTest, Inc., a Colorado cannabis laboratory and testing technology company and will become a wholly owned subsidiary of HempTech.

Hemispherx Biopharma (NYSE MKT:HEB)
announced that one of its advanced stage biological products, Alferon® N, significantly inhibited the replication of the MERS virus in vitro. MERS-CoV is a recently emerged human coronavirus responsible for the lethal pulmonary syndrome known as MERS (Middle East Respiratory Syndrome).

Immunomedics, Inc., (Nasdaq:IMMU)
today announced that it will host a conference call and live audio webcast on Thursday, May 8, 2014 at 10:00 a.m. Eastern Time to discuss financial results for the third quarter of fiscal year 2014, and review key clinical developments and future planned activities.

Integra LifeSciences Holdings Corporation (Nasdaq:IART), a world leader in medical technology, will visit the NASDAQ MarketSite in Times Square.

Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB)
, the leading developer of advanced spider silk based fibers, announced today that Warwick Mills, Inc., a leader in the engineering and development of advanced technical textiles and protective materials, is preparing to weave the first textiles with Kraig's Monster Silk™ recombinant spider silk.

In a proactive effort to manage its cash, LipoScience, Inc. (Nasdaq:LPDX) today announced a reduction in workforce.

MacroGenics, Inc. (Nasdaq:MGNX)
, a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the presentation of pre-clinical data on MGD010, a bi-specific Dual-Affinity Re-targeting (DART®) protein, demonstrating its ability to inhibit B-cell activation without B-cell depletion, which could provide a novel treatment option for patients with autoimmune disorders.

Nature's Sunshine Products, Inc. (Nasdaq:NATR)
, a leading natural health and wellness company engaged in the manufacture and direct selling of nutritional and personal care products, today announced that it will report first quarter 2014 financial results for the period ended March 31, 2014, on Wednesday, May 7, 2014, at 4:00 p.m. Eastern Time.

NeoStem, Inc. (Nasdaq:NBS)
, a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC, will present at multiple upcoming conferences in May.

Pacific Shore Holdings, Inc's. (OTCBB:PSHR)
, Nature-Cide Division, a pest management service company that's also engaged in the manufacturing of all-natural and eco-friendly pesticides, is excited to announce that they will be attending the National Hardware Convention in Las Vegas, NV, May 6 through May 8 at the Las Vegas Convention Center Booth 11567.

Portola Pharmaceuticals, Inc. (Nasdaq:PTLA)
today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended March 31, 2014 and provide a general business overview on Monday, May 12, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG)
today announced that data from the phase 1 randomized, placebo-controlled clinical study of SHAPE (formerly SHP-141) in Stage IA –IIA Cutaneous T Cell Lymphoma will be presented at the annual Society of Investigative Dermatology Meeting to be held in Albuquerque, New Mexico from May 7– May 10, 2014.

TG Therapeutics, Inc. (Nasdaq:TGTX)
, will participate in the 39th Annual Deutsche Bank Healthcare Conference being held at The InterContinental in Boston, MA.

Versartis, Inc. (Nasdaq:VSAR)
, an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD), today announced financial results for the first quarter ended March 31, 2014.

Xenetic Biosciences, Inc. (OTCBB:XBIO)
, a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, today announced the appointment of Mark Leuchtenberger as Non-Executive Chairman of the Board of Directors.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus